Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Butylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.67 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 9/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.43 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.43 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylamine SCHEMBL103293 | 1.00 | — | — | |
| Butylamine SCHEMBL5001577 | 1.00 | DNM1 (0.67) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Butylamine SCHEMBL27308164 | 1.00 | — | — | |
| Butylamine SCHEMBL6933505 | 1.00 | — | — | |
| Butylamine SCHEMBL2051232 | 0.96 | — | — | |
| Butylamine SCHEMBL4335242 | 0.96 | — | — | |
| Butylamine SCHEMBL10449621 | 0.96 | — | — | |
| Butylamine SCHEMBL896455 | 0.96 | — | — | |
| Butylamine SCHEMBL571241 | 0.96 | — | — | |
| Butylamine SCHEMBL4335244 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115103930-A | Method for reducing or preventing corrosion or fouling by acidic compounds | 栗田工业株式会社 | 2022-09-23 | — | — | CN | claimed |
| CN-114292614-A | Preparation method of modified silicon dioxide-epoxy resin composite slurry | 西陇科学股份有限公司 | 2022-04-08 | — | — | CN | claimed |
| US-7687622-B2 | Process for preparing quetiapine fumarate | TEVA PHARMACEUTICAL INDUSTRIES, LTD (IL) | 2010-03-30 | — | — | US | claimed |
| EP-0704094-B1 | POLYMERS FOR OPTICAL DEVICES | CAMBRIDGE DISPLAY TECH LTD (GB) | 2001-08-08 | — | — | EP | claimed |
| US-5514878-A | Polymers for electroluminescent devices | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 1996-05-07 | — | — | US | claimed |
| EP-0704094-A1 | POLYMERS FOR OPTICAL DEVICES | Cambridge Display Technology Limited (GB) | 1996-04-03 | — | — | EP | claimed |
| WO-1994029883-A1 | POLYMERS FOR OPTICAL DEVICES | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 1994-12-22 | — | — | WO | claimed |
| CN-120039837-A | Two-dimensional vanadium-based nitride electrode material for water-based ion battery, and preparation method and application thereof | 江西科技师范大学 | 2025-05-27 | — | — | CN | disclosed |
| CN-114728265-B | Particulate water absorbing agent and method for producing same | 株式会社日本触媒 | 2025-05-02 | — | — | CN | disclosed |
| CN-119497822-A | Immunoassay method based on carbon nanomaterial and method for detecting target antigen by immunoassay method | 李知勋 | 2025-02-21 | — | — | CN | disclosed |
| CN-119371422-A | Methods for preparing Toll-like receptor modulator compounds | 吉利德科学公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-119335811-A | Resist composition and pattern forming method | 湖北鼎龙控股股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-114341217-B | Aqueous resin composition, aqueous paint, and plastic molded article coated with the aqueous paint | DIC株式会社 | 2024-12-27 | — | — | CN | disclosed |
| US-20130245043-A1 | SUBSTITUTED IMIDAZOPYRIMIDIN-5(6H)-ONES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-09-19 | — | — | US | disclosed |
| US-20130224876-A1 | A METHOD AND DEVICE FOR DETECTING ALKYLATING AGENTS | Univeristy College Cardiff Consultants Limited | 2013-08-29 | — | — | US | disclosed |
| US-7767806-B2 | Hyaluronic acid modification products and drug carriers using them | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20070031503-A1 | encapsulates low molecular weight drugs and provides sustained-release over long term, control of blood residence, dispersible in aqueous solution, and improved biocompatibility; hyaluronidase resistance | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1666518-A1 | HYALURONIC ACID MODIFICATION PRODUCTS AND DRUG CARRIERS USING THEM | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-0536324-B1 | METHOD FOR FORMING AN AMINO ACID THIOHYDANTOIN USING AN N-SUBSTITUTED KETENIMINE ACTIVATOR | PERKIN ELMER CORP (US) | 1998-11-25 | — | — | EP | disclosed |
| US-5051368-A | Method for forming an amino acid thiohydantoin using an N-substituted ketenimine activator | APPLIED BIOSYSTEMS, INC. (US) | 1991-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070031503-A1 | encapsulates low molecular weight drugs and provides sustained-release over long term, control of blood residence, dispersible in aqueous solution, and improved biocompatibility; hyaluronidase resistance | CD44, VEGFA, MMP1 | MEN1 2717/4885THRB 3257/4885DNM1 4443/4885 |
| US-20130245043-A1 | SUBSTITUTED IMIDAZOPYRIMIDIN-5(6H)-ONES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM3 | MEN1 4450/4885THRB 678/4885DNM1 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.